Literature DB >> 28819878

Aspergillus Bronchitis in Patients with Cystic Fibrosis.

Claudia Brandt1, Jobst Roehmel1, Volker Rickerts2, Volker Melichar3, Nadja Niemann4, Carsten Schwarz5.   

Abstract

Aspergillus fumigatus frequently colonizes the airways of patients with cystic fibrosis (CF) and may cause various severe infections, such as bronchitis. Serological data, sputum dependent markers and longitudinal data of treated cases of Aspergillus bronchitis were evaluated for further description of this infection. This study, which comprises three substudies, aimed to analyze epidemiological data of Aspergillus in CF and the entity of Aspergillus bronchitis. In a first step, data of the German Cystic Fibrosis Registry were used to evaluate the frequency of Aspergillus colonization in patients with CF (n = 2599). Then a retrospective analysis of 10 cases of Aspergillus bronchitis was performed to evaluate longitudinal data for lung function and clinical presentation parameters: sputum production, cough and physical capacity. Finally, a prospective cohort study (n = 22) was conducted to investigate serological markers for Aspergillus bronchitis: total serum IgE, specific serum IgE, specific serum IgG, as well as sputum galactomannan, real-time PCR detection of Aspergillus DNA in sputum and fungal cultures. Analysis of the German CF registry revealed an Aspergillus colonization rate of 32.5% among the 2599 patients. A retrospective data analysis of 10 treated cases revealed the clinical course of Aspergillus bronchitis, including repeated positive sputum culture findings for A. fumigatus, no antibiotic treatment response, total serum IgE levels <200 kU/l, no observation of new pulmonary infiltrates and appropriate antifungal treatment response. Antifungal treatment durations of 4 ± 1.6 (2-6) weeks significantly reduced cough (P = 0.0067), sputum production (P < 0.0001) and lung function measures (P = 0.0358) but not physical capacity (P = 0.0794). From this retrospective study, a prevalence of 1.6% was calculated. In addition, two cases of Aspergillus bronchitis were identified in the prospective cohort study according to immunological, molecular and microbiological parameters. A prevalence of 9% was assessed. Aspergillus bronchitis appears to occur in a minority of colonized CF patients. Antifungal treatment may reduce respiratory symptoms and restore lung function.

Entities:  

Keywords:  Aspergillus fumigatus; Bronchitis; Colonization; Cystic Fibrosis; Pneumonia

Mesh:

Substances:

Year:  2017        PMID: 28819878     DOI: 10.1007/s11046-017-0190-0

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  23 in total

1.  The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis.

Authors:  Reshma Amin; Annie Dupuis; Shawn D Aaron; Felix Ratjen
Journal:  Chest       Date:  2009-06-30       Impact factor: 9.410

Review 2.  Cystic fibrosis genetics: from molecular understanding to clinical application.

Authors:  Garry R Cutting
Journal:  Nat Rev Genet       Date:  2014-11-18       Impact factor: 53.242

3.  Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Authors:  D E Geller; H Kaplowitz; M J Light; A A Colin
Journal:  Chest       Date:  1999-09       Impact factor: 9.410

4.  Aspergillus bronchitis without significant immunocompromise.

Authors:  Ales Chrdle; Sahlawati Mustakim; Rowland J Bright-Thomas; Caroline G Baxter; Timothy Felton; David W Denning
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

5.  Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis.

Authors:  Kaïssa de Boer; Katherine L Vandemheen; Elizabeth Tullis; Steve Doucette; Dean Fergusson; Andreas Freitag; Nigel Paterson; Mary Jackson; M Diane Lougheed; Vijay Kumar; Shawn D Aaron
Journal:  Thorax       Date:  2011-06-15       Impact factor: 9.139

6.  Microbial colonization and lung function in adolescents with cystic fibrosis.

Authors:  Andreas Hector; Tobias Kirn; Anjali Ralhan; Ute Graepler-Mainka; Sina Berenbrinker; Joachim Riethmueller; Michael Hogardt; Marlies Wagner; Andreas Pfleger; Ingo Autenrieth; Matthias Kappler; Matthias Griese; Ernst Eber; Peter Martus; Dominik Hartl
Journal:  J Cyst Fibros       Date:  2016-02-05       Impact factor: 5.482

Review 7.  The clinical spectrum of pulmonary aspergillosis.

Authors:  Chris Kosmidis; David W Denning
Journal:  Thorax       Date:  2014-10-29       Impact factor: 9.139

8.  Aspergillus bronchitis in cystic fibrosis.

Authors:  David Shoseyov; Keith G Brownlee; Steven P Conway; Eitan Kerem
Journal:  Chest       Date:  2006-07       Impact factor: 9.410

Review 9.  Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference.

Authors:  David A Stevens; Richard B Moss; Viswanath P Kurup; Alan P Knutsen; Paul Greenberger; Marc A Judson; David W Denning; Reto Crameri; Alan S Brody; Michael Light; Marianne Skov; William Maish; Gianni Mastella
Journal:  Clin Infect Dis       Date:  2003-10-01       Impact factor: 9.079

10.  Increased prevalence and altered species composition of filamentous fungi in respiratory specimens from cystic fibrosis patients.

Authors:  Signe M Nielsen; Lise Kristensen; Annette Søndergaard; Kurt J Handberg; Jørgen Stenderup; Niels Nørskov-Lauritsen
Journal:  APMIS       Date:  2014-04-03       Impact factor: 3.205

View more
  24 in total

1.  The presence of Aspergillus fumigatus is associated with worse respiratory quality of life in cystic fibrosis.

Authors:  Gina Hong; Kevin Alby; Sharon C W Ng; Victoria Fleck; Christina Kubrak; Ronald C Rubenstein; Daniel J Dorgan; Steven M Kawut; Denis Hadjiliadis
Journal:  J Cyst Fibros       Date:  2019-08-21       Impact factor: 5.482

Review 2.  Progress and challenges in fungal lung disease in cystic fibrosis.

Authors:  Gina Hong
Journal:  Curr Opin Pulm Med       Date:  2022-09-19       Impact factor: 2.868

3.  Persistent Aspergillus fumigatus infection in cystic fibrosis: impact on lung function and role of treatment of asymptomatic colonization-a registry-based case-control study.

Authors:  Axel Blomquist; Malin Inghammar; Mahasin Al Shakirchi; Petrea Ericson; Christina Krantz; Marcus Svedberg; Anders Lindblad; Lisa I Påhlman
Journal:  BMC Pulm Med       Date:  2022-07-05       Impact factor: 3.320

4.  Clinical Impact of Aspergillus fumigatus in Children with Cystic Fibrosis.

Authors:  Valentina Fainardi; Chiara Sodini; Michela Deolmi; Andrea Ciuni; Kaltra Skenderaj; Maria Bice Stabile; Cosimo Neglia; Elena Mariotti Zani; Cinzia Spaggiari; Nicola Sverzellati; Susanna Esposito; Giovanna Pisi
Journal:  Microorganisms       Date:  2022-03-29

Review 5.  Emerging Fungal Threats in Cystic Fibrosis.

Authors:  C Schwarz; P Eschenhagen; J P Bouchara
Journal:  Mycopathologia       Date:  2021-07-28       Impact factor: 2.574

Review 6.  New Perspectives in the Diagnosis and Management of Allergic Fungal Airway Disease.

Authors:  Andrew J Wardlaw; Eva-Maria Rick; Leyla Pur Ozyigit; Alys Scadding; Erol A Gaillard; Catherine H Pashley
Journal:  J Asthma Allergy       Date:  2021-05-25

Review 7.  Fungal Infection and Inflammation in Cystic Fibrosis.

Authors:  T Spencer Poore; Gina Hong; Edith T Zemanick
Journal:  Pathogens       Date:  2021-05-18

Review 8.  Allergic fungal airways disease (AFAD): an under-recognised asthma endotype.

Authors:  Catherine H Pashley; Andrew J Wardlaw
Journal:  Mycopathologia       Date:  2021-05-27       Impact factor: 2.574

9.  Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: An international survey.

Authors:  Gina Hong; Sameer Desai; Richard B Moss; Patience Eschenhagen; Bradley S Quon; Carsten Schwarz
Journal:  J Cyst Fibros       Date:  2021-07-29       Impact factor: 5.527

10.  A retrospective 'real-world' cohort study of azole therapeutic drug monitoring and evolution of antifungal resistance in cystic fibrosis.

Authors:  M Di Paolo; L Hewitt; E Nwanko; M Ni; A Vidal-Diaz; M C Fisher; D Armstrong-James; A Shah
Journal:  JAC Antimicrob Resist       Date:  2021-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.